Predictors of hospital-acquired urinary tract-related bloodstream infection.

Link to article at PubMed

Related Articles

Predictors of hospital-acquired urinary tract-related bloodstream infection.

Infect Control Hosp Epidemiol. 2012 Oct;33(10):1001-7

Authors: Greene MT, Chang R, Kuhn L, Rogers MA, Chenoweth CE, Shuman E, Saint S


Objective.?Bloodstream infection (BSI) secondary to nosocomial urinary tract infection is associated with substantial morbidity, mortality, and additional financial costs. Our objective was to identify predictors of nosocomial urinary tract-related BSI. Design.?Matched case-control study. Setting.?Midwestern tertiary care hospital. Patients.?Cases ([Formula: see text]) were patients with a positive urine culture obtained more than 48 hours after admission and a blood culture obtained within 14 days of the urine culture that grew the same organism. Controls ([Formula: see text]), selected by incidence density sampling, included patients with a positive urine culture who were at risk for BSI but did not develop one. Methods.?Conditional logistic regression and classification and regression tree analyses. Results.?The most frequently isolated microorganisms that spread from the urinary tract to the bloodstream were Enterococcus species. Independent risk factors included neutropenia (odds ratio [OR], 10.99; 95% confidence interval [CI], 5.78-20.88), renal disease (OR, 2.96; 95% CI, 1.98-4.41), and male sex (OR, 2.18; 95% CI, 1.52-3.12). The probability of developing a urinary tract-related BSI among neutropenic patients was 70%. Receipt of immunosuppressants (OR, 1.53; 95% CI, 1.04-2.25), insulin (OR, 4.82; 95% CI, 2.52-9.21), and antibacterials (OR, 0.66; 95% CI, 0.44-0.97) also significantly altered risk. Conclusions.?The heightened risk of urinary tract-related BSI associated with several comorbid conditions suggests that the management of nosocomial bacteriuria may benefit from tailoring to certain patient subgroups. Consideration of time-dependent risk factors, such as medications, may also help guide clinical decisions in reducing BSI.

PMID: 22961019 [PubMed - in process]

Leave a Reply

Your email address will not be published. Required fields are marked *